Overview

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

Status:
Not yet recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This is a two-part study of the safety, tolerability, and efficacy of topically administered WST-057 for 16 weeks in subjects with HIV with sensory polyneuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
WinSanTor, Inc